BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients
Combining BioXcel's BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company. Dr. Luca Rastelli, BioXCel's vice-president for oncology research and development, presented the poster, "The synergy between BXCL701, a DPP inhibitor, and immune checkpoint inhibitors discovered using AI and Big Data analytics," April 3 at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, D.C. “BXCL701, our first-in-class small molecule immuno-modulator, stimulates a pro-inflammatory, anti-tumor cellular response that is complementary to the one mediated by immune-checkpoints," Rastelli said in a press release. "In addition, genomic data analysis of patients with CRPC showed that BXCL701 molecular targets are upregulated in patients previously treated with the androgen deprivation therapies enzalutamide or abiraterone. These data support our plan to develop BXCL701 as a monotherapy and in combination with immune-checkpoint inhibitors in advanced CRPC.” BXCL701 is an immunotherapy with two mechanisms of action: it targets the fibroblast activator protein, which inhibits immuno-suppressive fibroblasts within tumors, and interacts with the tumor blood vessels, helping immune ce
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *